Volume 27, Issue 2 pp. 584-589
Original Article
Free Access

Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: The influence of virus C infection

Maria Jose Moran

Maria Jose Moran

Laboratoire de Pathologie Moléculaire et Thérapie Génique, Université de Bordeaux II, Bordeaux, France

Dr. Moran and Dr. Fontanellas contributed equally to this article.

Search for more papers by this author
Antonio Fontanellas Ph.D.

Corresponding Author

Antonio Fontanellas Ph.D.

Laboratoire de Pathologie Moléculaire et Thérapie Génique, Université de Bordeaux II, Bordeaux, France

Dr. Fontanellas is a postdoctoral TMR Marie Curie Research Fellow

Laboratoire de Pathologie Moléculaire et Thérapie Génique. Université de Bordeaux II, 146 rue Léo Saignat, 33076 Bordeaux Cédex, France. Fax: 33-5-56-98-33-48===Search for more papers by this author
Eric Brudieux

Eric Brudieux

Service d'Hépato-Gastroentérologie, Hopital du Haut-Lévêque, CHU de Bordeaux, France

Search for more papers by this author
Isabelle Hombrados

Isabelle Hombrados

Laboratoire de Pathologie Moléculaire et Thérapie Génique, Université de Bordeaux II, Bordeaux, France

Search for more papers by this author
Victor de Ledinghen

Victor de Ledinghen

Service d'Hépato-Gastroentérologie, Hopital du Haut-Lévêque, CHU de Bordeaux, France

Search for more papers by this author
Patrice Couzigou

Patrice Couzigou

Service d'Hépato-Gastroentérologie, Hopital du Haut-Lévêque, CHU de Bordeaux, France

Search for more papers by this author
Hubert de Verneuil

Hubert de Verneuil

Laboratoire de Pathologie Moléculaire et Thérapie Génique, Université de Bordeaux II, Bordeaux, France

Search for more papers by this author
Rafael Enriquez De Salamanca

Rafael Enriquez De Salamanca

Servicio de Medicina Interna Hospital Universitario 12 de Octubre, Madrid, Spain

Search for more papers by this author
First published: 30 December 2003
Citations: 43

Abstract

Porphyria cutanea tarda (PCT) is caused by a decreased activity of the hepatic enzyme uroporphyrinogen decarboxylase (URO-D). This deficiency causes overproduction, hepatic deposition, and increased excretion of uroporphyrin. Iron overload and hepatic viral infections are considered aggravating factors of the disease. Two forms of PCT have been described, as follows: a familial one with an inherited decrease of URO-D activity in all tissues and a sporadic one with a decreased activity of URO-D restricted to the liver. To assess whether the hepatic URO-D returns to normal during a remission of the disease, this activity was measured in liver biopsy samples in 24 sporadic PCT patients. The hepatic and urinary porphyrin concentrations were also measured. Viral status and histopathological findings were analyzed to assess their involvement in PCT. Six patients treated by phlebotomy to reduce hepatic iron and who were considered to be in clinical remission, characterized by a disappearance of cutaneous lesions, showed higher hepatic URO-D activities and lower hepatic porphyrin concentrations than did patients with overt PCT. The medians of these variables, however, did not achieve normal values. The hepatic URO-D activity showed a significant inverse relationship with both hepatic porphyrins and urinary uroporphyrin excretion. Hepatic URO-D activity was not reduced by hepatitis C virus (HCV) infection and liver damage. We conclude that the achievement of remission in PCT largely depends on the transient normalization of hepatic URO-D activity. A small increase in hepatic coproporphyrin in nonporphyric patients could reflect hepatic injury/iron/alcohol-induced oxidative stress oxidizing the accumulated heme precursors rather than a direct effect on hepatic URO-D enzyme.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.